Polypragmasy at treatment of H. pylori infection in patients with concomitant diseases of other organs and systems. How to prevent side effects related to drug interactions?
Abstract
The aim of the publication. Issues of drug interaction, side effects development at patients with combined diseases, requiring eradication treatment, are taken into account.
Original positions. Being based on literature data and own experience, authors demonstrated, that drug interactions are observed in vast majority of cases at simultaneous prescription of five drugs and more. As eradication therapy implicates addition to treatment of at least 3 pharmaceuticals of which antibiotics are strictly specified, it is extremely desirable to choose proton pump inhibitor (PPI) with lower affinity to cytochrome Р450. Pantoprazole conform to these requirements, and surpasses all other PPIs in this respect.
Conclusion. Authors believe, taking into account available data on drug interactions, that at patients with multiple morbidity pantoprazole is preferable to other antisecretory agents.
About the Authors
S. G. Burkov
ФГУ «Поликлиника № 3» Управления делами Президента РФ
Russian Federation
Russian Federation
N. V. Shornikova
ФГУ «Поликлиника № 3» Управления делами Президента РФ
Russian Federation
Russian Federation
References
1. Афонин А.В., Молчанова А.Ю., Драпкина О.М., Ивашкин В.Т. Ингибиторы протонной помпы и эради кационная терапия в лечении абдоминального болевого синдрома при язвенной болезни двенадцатиперстной кишки // Рос. мед. вести. – 2009. – № 3. – С. 1–4.
2. Ивашкин В.Т., Трухманов А.С. Современный подход к терапии гастроэзофагеальной рефлюксной болезни во врачебной практике // Рос. мед. журн. – 2003. – № 2. – С. 43–48.
3. Исаков В.А. Безопасность ингибиторов протонного насоса при длительном применении // Клин. фарма кол. тер. – 2004. – № 1. – С. 26–32.
4. Логинов А.Ф. Возможности использования пантопразо ла в терапии гастроэзофагеальной рефлюксной болезни // Фарматека. – 2009. – № 13. – С. 29–33.
5. Лоуренс Д.Р., Бенитт П.Н. Клиническая фармаколо гия: пер. с англ.: В 2-х т. – Т. 1. – М.: Медицина, 1991. – 656 с.
6. Яковенко Э.П., Яковенко А.В., Агафонова Н.А. и др. Пептические язвы, патогенетические подходы к терапии // Фарматека. – 2008. – № 13. – С. 62–67.
7. Huber R., Hartman M., Bliesath H. et al. Pharmacokinetics of pantoprazole in man // Int. J. Clin. Pharmacol. Ther. – 1996. – Vol. 34, N 5. – P. 185–94.
8. Malfertheiner P., Megraud F., O’Morain C. et al. Current concepts in the management of Helicobacter pylori infection, the Maastricht III Consensus Report // Gut. – 2007. – Vol. 56, N 6. – P. 772–781.
9. National Center for Health Statistics: «NCHS Data Brief No 42, September 2010» // www. Webmd.com.
10. Protonix (pantoprazole sodium) delayed-release tablets package insert. – Philadelphia: Wyeth Laboratories, 2000.
11. Sachs G. Synthesis or Rupture: duration of acid inhibi tion by PPIs. Research Highlights Driving Therapeutic Advance. ALTA-NA Pharma Symosium, 2002. – P. 9–10.
Review
For citations:
Burkov S.G., Shornikova N.V. Polypragmasy at treatment of H. pylori infection in patients with concomitant diseases of other organs and systems. How to prevent side effects related to drug interactions? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2011;21(3):47-51. (In Russ.)
Views:
49
Email this article 
